Xeltis today announced encouraging preliminary data for its Xabg coronary artery bypass conduit (CABG) device.
Early results from a European clinical trial demonstrate positive safety and patency among patients with multi-vessel atherosclerotic coronary artery disease (CAD).
According to a news release, CABG, an invasive procedure, often requires multiple painful vein grafts with a high risk of complications.
Xabg, a novel, biorestorative, polymeric conduit, enables blood flow in CAD patients. Xeltis developed it using its proprietary Endogenous Tissue Restoration (ETR) platform. It features unique regenerative properties, enabling living tissue to replace it over time.
The clinical trial shows Xabg functioning well, with “excellent” flow in patients, Xeltis said. The company believes this underscores the potential of the conduit to eliminate the need for vein harvesting. It says the device could transform the bypass surgery landscape with the aim of longer-term durability.
Xabg, Xeltis’ second product in development, follows aXess, a restorative vascular access conduit. The company currently has clinical trials underway in Europe and the U.S. for aXess as well.
“Despite suboptimal performance, 80% of CABG procedures rely on vein grafts – Xeltis has the potential to revolutionize that. The encouraging safety and patency data is a major milestone for Xeltis and demonstrates that Xabg has the potential to significantly improve outcomes for patients with coronary artery disease,” said Paulo Neves, chief medical officer, Xeltis. “We are grateful to all those involved in the trial and look forward to continuing patient enrollment and treatment.”
